ThermoGenesis Holdings, Inc

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

RANCHO CORDOVA, Calif., Aug. 11, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings To Delay Second Quarter 2020 Earnings Release And Conference Call Until Friday August 14, 2020

ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock

RANCHO CORDOVA, Calif., June 23, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that, pursuant to its existing, exclusive global distribution agreement...

ThermoGenesis Announces Corning's Commercial Launch of the X-SERIES® Cell Processing Products Developed by ThermoGenesis

RANCHO CORDOVA, Calif., June 8, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East...

ThermoGenesis Announces That Results of ImmuneCyte's Licensed Neutralizing Antibody Therapeutics for COVID-19 Were Published in bioRxiv

RANCHO CORDOVA, Calif., May 28, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced a change in location of its 2020 Annual Meeting of Stockholders to be held...

ThermoGenesis Holdings Announces Change In Location Of 2020 Annual Meeting Of Stockholders

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2020 Results - Earnings Call Transcript

RANCHO CORDOVA, Calif., May 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the first quarter ended March 31, 2020...

ThermoGenesis Holdings Announces Financial Results for First Quarter Ended March 31, 2020 and Provides Corporate Update

Black Diamond Therapeutics

Minerva Neurosciences

Sprout Social

Zynex Inc

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Disappointing Data

As of late, it has definitely been a great time to be an investor in ThermoGenesis Holdings, Inc. (THMO).

ThermoGenesis Holdings, Inc. (THMO) Shares March Higher, Can It Continue?

Thermogenesis Holdings Inc (NASDAQ: THMO) shares are trading higher on Thursday.

Why Thermogenesis Is Trading Higher Today

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2019 Results - Earnings Call Transcript

The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing

Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q2 2019 Results - Earnings Call Transcript

The shares of Cesca Therapeutics have been sliding for a long time, producing large losses in the company accounts and for holders.

There Is Life Left In Cesca Therapeutics

Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q1 2019 Results - Earnings Call Transcript

Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know

Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q4 2018 Results - Earnings Call Transcript

News for ThermoGenesis Holdings, Inc Stock (THMO)